Compare INTZ & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INTZ | NEUP |
|---|---|---|
| Founded | 1983 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 14.9M |
| IPO Year | 2020 | 2002 |
| Metric | INTZ | NEUP |
|---|---|---|
| Price | $0.41 | $2.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 173.6K | 32.8K |
| Earning Date | 11-12-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,015,000.00 | $1,174,165.00 |
| Revenue This Year | $22.62 | N/A |
| Revenue Next Year | $26.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.56 | N/A |
| 52 Week Low | $0.47 | $2.54 |
| 52 Week High | $1.56 | $5.53 |
| Indicator | INTZ | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 34.65 | 16.20 |
| Support Level | N/A | N/A |
| Resistance Level | $0.89 | $4.15 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 3.15 | 2.11 |
Intrusion Inc is a cybersecurity company based in Plano, Texas. The company offers its customers access to its exclusive threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol addresses. Its platform combines threat intelligence, malicious traffic identification, and automated threat response, and is designed to help organizations proactively identify and stop malicious activity in their networks. Its solutions include INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. The company operates in single segment.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.